ABCL
Price
$3.62
Change
-$0.35 (-8.82%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
1.18B
103 days until earnings call
Intraday BUY SELL Signals
DNA
Price
$8.00
Change
-$0.37 (-4.43%)
Updated
Nov 13, 04:59 PM (EDT)
Capitalization
484.72M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs DNA

Header iconABCL vs DNA Comparison
Open Charts ABCL vs DNABanner chart's image
AbCellera Biologics
Price$3.62
Change-$0.35 (-8.82%)
Volume$71.39K
Capitalization1.18B
Ginkgo Bioworks Holdings
Price$8.00
Change-$0.37 (-4.43%)
Volume$9.97K
Capitalization484.72M
ABCL vs DNA Comparison Chart in %
View a ticker or compare two or three
VS
ABCL vs. DNA commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and DNA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (ABCL: $3.97 vs. DNA: $8.36)
Brand notoriety: ABCL and DNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 53% vs. DNA: 84%
Market capitalization -- ABCL: $1.18B vs. DNA: $484.72M
ABCL [@Biotechnology] is valued at $1.18B. DNA’s [@Biotechnology] market capitalization is $484.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileDNA’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • DNA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABCL and DNA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while DNA’s TA Score has 4 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 6 bearish.
  • DNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DNA is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -15.35% price change this week, while DNA (@Biotechnology) price change was -27.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

ABCL is expected to report earnings on Feb 24, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($1.18B) has a higher market cap than DNA($485M). ABCL YTD gains are higher at: 35.495 vs. DNA (-14.868). ABCL has higher annual earnings (EBITDA): -197.92M vs. DNA (-292.97M). ABCL has more cash in the bank: 553M vs. DNA (474M). ABCL has less debt than DNA: ABCL (142M) vs DNA (429M). DNA has higher revenues than ABCL: DNA (231M) vs ABCL (32.9M).
ABCLDNAABCL / DNA
Capitalization1.18B485M244%
EBITDA-197.92M-292.97M68%
Gain YTD35.495-14.868-239%
P/E RatioN/AN/A-
Revenue32.9M231M14%
Total Cash553M474M117%
Total Debt142M429M33%
TECHNICAL ANALYSIS
Technical Analysis
ABCLDNA
RSI
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
N/A
Bullish Trend 21 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
74%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
DNA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PXWGX26.830.14
+0.52%
Impax US Sustainable Economy Investor
JDIBX17.740.08
+0.45%
JHancock Disciplined Value Intl A
NMFAX17.050.02
+0.12%
Nationwide BNY Mellon Dyn US Core A
RBCRX13.11-0.03
-0.23%
RBC China Equity R6
VRSCX25.57-0.08
-0.31%
Voya SmallCap Opportunities Port R6

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
-1.00%
RXRX - ABCL
59%
Loosely correlated
-1.27%
CRSP - ABCL
59%
Loosely correlated
-5.47%
VCYT - ABCL
56%
Loosely correlated
-0.84%
ABSI - ABCL
55%
Loosely correlated
-1.45%
BEAM - ABCL
52%
Loosely correlated
-2.71%
More